Role of FGFR3 in bladder cancer: Treatment landscape and future challenges

Bladder cancer is a heterogeneous malignancy and is responsible for approximately 3.2% of new diagnoses of cancer per year (Sung et al., 2021). Fibroblast Growth Factor Receptors (FGFRs) have recently emerged as a novel therapeutic target in cancer. In particular, FGFR3 genomic alterations are potent oncogenic drivers in bladder cancer and represent predictive biomarkers of response to FGFR inhibitors. Indeed, overall ∼50% of bladder cancers have somatic mutations in the FGFR3 -coding sequence (Cappellen et al., 1999; Turner and Grose, 2010). FGFR3 gene rearrangements are typical alterations in bladder cancer (Nelson et al., 2016; Parker et al., 2014). In this review, we summarize the most relevant evidence on…

• AI
  Associazione Italiana per la Ricerca sul Cancro

  Awards: IG2018-21339, MFAG2022-27826, MFGA2018-21505, 26795
• FI
  Fondazione Italiana per la Ricerca sul Cancro

  Awards: MFGA2018–21505, MFAG2022-27826, IG2018–21339